Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease

Journal of Autoimmunity

Volumn 57, Issue , 2015, Pages 60-65

  Roberts, Darren M ^a,b   Jones, Rachel B ^a   Smith, Rona M ^a   Alberici, Federico ^a,c   Kumaratne, Dinakantha S ^a   Burns, Stella ^a   Jayne, David R W ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

ANCA; Autoimmune; Hypogammaglobulinemia; Infection; Rituximab; Vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; RITUXIMAB; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; AUTOIMMUNE DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SMALL VESSEL VASCULITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; AGAMMAGLOBULINEMIA; AUTOIMMUNE DISEASES; BLOOD; CHEMICALLY INDUCED; INCIDENCE; MIDDLE AGED; PROGNOSIS; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER; TREATMENT OUTCOME; VASCULITIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; TERTIARY CARE CENTERS; TREATMENT OUTCOME; VASCULITIS; YOUNG ADULT;

EID: 84922786242     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.11.009     Document Type: Article

References (43)

1. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
2. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. NEngl J Med 2004, 350:2572-2581.
3. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. NEngl J Med 2010, 363:221-232.
4. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. NEngl J Med 2010, 363:211-220.
5. Smith R.M., Jones R.B., Guerry M.J., Laurino S., Catapano F., Chaudhry A., et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:3760-3769.
6. Miloslavsky E.M., Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013, 65:2441-2449.
7. Walker A.R., Kleiner A., Rich L., Conners C., Fisher R.I., Anolik J., et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 2008, 26:431-433.
8. Irie E., Shirota Y., Suzuki C., Tajima Y., Ishizawa K., Kameoka J., et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010, 91:501-508.
9. Hicks L.K., Woods A., Buckstein R., Mangel J., Pennell N., Zhang L., et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transpl 2009, 43:701-708.
10. Lim S.H., Esler W.V., Zhang Y., Zhang J., Periman P.O., Burris C., et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 2008, 49:152-153.
11. Nishio M., Fujimoto K., Yamamoto S., Endo T., Sakai T., Obara M., et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol 2006, 77:226-232.
12. Buser A., Stern M., Arber C., Medinger M., Halter J., Rovo A., et al. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?. Bone Marrow Transpl 2008, 42:483-487.
13. Cabanillas F., Liboy I., Pavia O., Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006, 17:1424-1427.
14. Wang Q.S., Zhao Y., Wang S.H., Li H.H., Huang W.R., Gao C.J., et al. Change of serum immunoglobulin level in patients with diffuse large B cell lymphoma after rituximab combined with chemotherapy. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui= J Exp Hematol/Chin Assoc Pathophysiol 2011, 19:676-679.
15. Arber C., Buser A., Heim D., Weisser M., Tyndall A., Tichelli A., et al. Septic polyarthritis with ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment. Bone Marrow Transpl 2007, 40:597-598.
16. Castagnola E., Dallorso S., Faraci M., Morreale G., Di Martino D., Cristina E., et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. JHematother Stem Cell Res 2003, 12:9-10.
17. Imashuku S., Teramura T., Morimoto A., Naya M., Kuroda H. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transpl 2004, 33:129-130.
18. Casulo C., Maragulia J., Zelenetz A.D. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013, 13:106-111.
19. Hansen D.A., Robbins B.A., Bylund D.J., Piro L.D., Saven A., Ellison D.J. Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell leukemia and chronic lymphocytic leukemia. Am J Clin Pathol 1994, 102:580-585.
20. Gottenberg J.E., Ravaud P., Bardin T., Cacoub P., Cantagrel A., Combe B., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632.
21. Keystone E., Fleischmann R., Emery P., Furst D.E., Van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
22. Furst D.E. Serum immunoglobulins and risk of infection: how low can you go?. Semin Arthritis Rheum 2009, 39:18-29.
23. Mease P.J., Cohen S., Gaylis N.B., Chubick A., Kaell A.T., Greenwald M., et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. JRheumatol 2010, 37:917-927.
24. Venhoff N., Effelsberg N.M., Salzer U., Warnatz K., Peter H.H., Lebrecht D., et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 2012, 7:e37626.
25. Besada E., Koldingsnes W., Nossent J.C. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatol (Oxford) 2013, 52:2041-2047.
26. Marco H., Smith R.M., Jones R.B., Guerry M.J., Catapano F., Burns S., et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 2014, 15:178.
27. Samson M., Audia S., Lakomy D., Bonnotte B., Tavernier C., Ornetti P. Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Jt Bone Spine 2011, 78:241-245.
28. Genovese M.C., Breedveld F.C., Emery P., Cohen S., Keystone E., Matteson E.L., et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009, 68:1894-1897.
29. Looney R.J., Srinivasan R., Calabrese L.H. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008, 58:5-14.
30. Lock R.J., Unsworth D.J. Immunoglobulins and immunoglobulin subclasses in the elderly. Ann Clin Biochem 2003, 40:143-148.
31. Kano G., Nakatani T., Yagi K., Sakamoto I., Imamura T. Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia. Immunol Lett 2014, 159:76-78.
32. Nishio M., Endo T., Fujimoto K., Yamamoto S., Obara M., Yamaguchi K., et al. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol 2009, 82:143-147.
33. van Vollenhoven R.F., Emery P., Bingham C.O., Keystone E.C., Fleischmann R.M., Furst D.E., et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013, 72:1496-1502.
34. Mariette X., Gottenberg J.E., Ravaud P., Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatol (Oxford) 2011, 50:222-229.
35. De La Torre I., Leandro M.J., Valor L., Becerra E., Edwards J.C., Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) 2012, 51:833-840.
36. Kanbayashi Y., Nomura K., Fujimoto Y., Yamashita M., Ohshiro M., Okamoto K., et al. Risk factors for infection in haematology patients treated with rituximab. Eur J Haematol 2009, 82:26-30.
37. Besada E., Koldingsnes W., Nossent J. Cyclophosphamide effect on immunoglobulins levels in AAV patients treated with long-term pre-emptive rituximab maintenance. la Presse Medicale Q Med Rev 2013, 42:267-268.
38. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. JClin Oncol Off J Am Soc Clin Oncol 1998, 16:2825-2833.
39. Isvy A., Meunier M., Gobeaux-Chenevier C., Maury E., Wipff J., Job-Deslandre C., et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Jt Bone Spine 2012, 79:365-369.
40. Knight A., Hallenberg H., Baecklund E. Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis-a case series. Clin Rheumatol 2014, 33:841-848.
41. Mcgregor J., Negrete-Lopez R., Poulton C., Kidd J., Weaver S., Goetz L., et al. Infectious complications related to treatment in an inception cohort of antineutrophil cytoplasmic antibody associated vasculitis. la Presse Medicale Q Med Rev 2013, 42:267.
42. Agarwal S., Cunningham-Rundles C. Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement. JAllergy Clin Immunol 2013, 131:1699-1701.
43. Roberts D.M., Jones R.B., Smith R.M., Alberici F., Kumaratne D.S., Burns S., Jayne D.R.W. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinaemia in autoimmune disease: a case series. J Autoimmunity 2014, 57:24-29. http://dx.doi.org/10.1016/j.jaut.2014.11.004.